Acquisition Announced
InMed Pharmaceuticals acquisition of Mentari Therapeutics
Announced 19 May 2026
Advisers
InMed Pharmaceuticals
Acquirer
- Financial adviser
- Legal adviser
- Target
- Mentari Therapeutics
- Acquirer
- InMed Pharmaceuticals
- Target based in
- United States (unverified)
- Buyer based in
- Canada (unverified)
- Sector
- Biotech
- Tags
- Biotech, Pharma
In the league tables
Similar deals
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Hansoh Pharmaceutical Group Co. stake in Avere Therapeutics Jul 2026 · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Zymeworks acquisition of Theravance Biopharma Jun 2026 · US$929m · Pharma
Sources
- 20 May 2026 Press release (PR Newswire), /C O R R E C T I O N -- InMed Pharmaceuticals/ prnewswire.com
- 21 May 2026 Gibson Dunn Advises Mentari Therapeutics on Merger With InMed Pharmaceuticals and Concurrent $290 Million Private Placement gibsondunn.com

